Devices

Warning Letter Sent to Beta Bionics

FDA has issued Beta Bionics a Warning Letter following an inspection of the company’s Irvine, CA, facility conducted 6/2025, according to a company regulatory filing. The agency issued the letter 1/29 after reviewing the company’s responses to a Form 483 listing inspectional observations identified during the inspection. In the letter, the agency reportedly cited deficiencies in Beta Bionics’ written responses rather than new inspection findings.

According to the company, the warning letter reiterates previously identified nonconformities related to its quality management system, medical device reporting practices, and procedures for corrections and removals. Those issues were first outlined in the Form 483 issued at the close of the inspection, it says.

Beta Bionics said the Warning Letter does not impose restrictions on its ability to manufacture, market, or distribute its products, nor does it limit the company’s ability to seek FDA 510(k) clearance for new devices.

In its filing, the company says it is preparing a formal written response and has already implemented several corrective actions addressing the cited deficiencies. Additional remediation steps may be taken based on FDA feedback.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome